Articles

Search Articles

Advanced search
Help

Catalogue

Articles

Databases

X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (1760) 1760
Publication (136) 136
Newsletter (100) 100
Book Review (27) 27
Book Chapter (22) 22
Newspaper Article (16) 16
Book / eBook (8) 8
Magazine Article (7) 7
Government Document (4) 4
Conference Proceeding (2) 2
Dissertation (1) 1
Report (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (1346) 1346
male (859) 859
female (766) 766
index medicus (736) 736
carbamates - adverse effects (602) 602
middle aged (572) 572
carbamates (566) 566
adult (545) 545
carbamates - therapeutic use (518) 518
animals (419) 419
aged (410) 410
pharmacology & pharmacy (354) 354
carbamates - administration & dosage (311) 311
treatment outcome (262) 262
drug therapy, combination (235) 235
pesticides (219) 219
toxicology (207) 207
carbamates - pharmacology (206) 206
dose-response relationship, drug (185) 185
sulfonamides - adverse effects (185) 185
analysis (164) 164
adolescent (158) 158
hiv infections - drug therapy (158) 158
sulfonamides - therapeutic use (157) 157
research (155) 155
carbamates - pharmacokinetics (154) 154
oncology (138) 138
drug therapy (136) 136
rats (136) 136
deoxycytidine - analogs & derivatives (132) 132
drug interactions (126) 126
environmental sciences (125) 125
toxicity (124) 124
capecitabine (121) 121
insecticides (121) 121
piperidines - therapeutic use (120) 120
sulfonamides - administration & dosage (118) 118
antiviral agents - therapeutic use (112) 112
pharmacokinetics (112) 112
double-blind method (110) 110
health aspects (110) 110
administration, oral (109) 109
clinical trials as topic (109) 109
hepatitis c, chronic - drug therapy (109) 109
phenylcarbamates (109) 109
mice (108) 108
drug administration schedule (106) 106
efficacy (105) 105
genotype (103) 103
diabetes mellitus, type 2 - drug therapy (102) 102
rivastigmine (102) 102
young adult (102) 102
piperidines - adverse effects (101) 101
therapy (101) 101
aged, 80 and over (100) 100
hepacivirus - genetics (100) 100
ritonavir - adverse effects (98) 98
safety (98) 98
fluorouracil - analogs & derivatives (97) 97
oral fluoropyrimidine carbamate (97) 97
hiv protease inhibitors - adverse effects (94) 94
ritonavir (93) 93
double-blind (92) 92
antiviral agents - adverse effects (91) 91
deoxycytidine - adverse effects (91) 91
ritonavir - administration & dosage (90) 90
time factors (90) 90
drug combinations (89) 89
medicine, general & internal (89) 89
ritonavir - therapeutic use (87) 87
deoxycytidine - administration & dosage (86) 86
hypoglycemic agents - therapeutic use (86) 86
infectious diseases (86) 86
public, environmental & occupational health (86) 86
clinical neurology (85) 85
care and treatment (84) 84
alzheimer disease - drug therapy (83) 83
anti-hiv agents - therapeutic use (82) 82
cholinesterase inhibitors - therapeutic use (82) 82
anti-hiv agents - adverse effects (76) 76
hepatitis c (76) 76
risk assessment (76) 76
medicine & public health (75) 75
uracil - analogs & derivatives (75) 75
exposure (73) 73
sulfonamides - pharmacokinetics (73) 73
hypoglycemic agents - adverse effects (72) 72
ribavirin (71) 71
cancer (70) 70
carbamate (70) 70
cholinesterase inhibitors - adverse effects (70) 70
hepatitis c virus (70) 70
insecticides - adverse effects (70) 70
hiv protease inhibitors - therapeutic use (69) 69
antiviral agents (68) 68
repaglinide (68) 68
risk factors (68) 68
deoxycytidine - therapeutic use (67) 67
antiviral agents - administration & dosage (66) 66
dosage and administration (66) 66
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (1806) 1806
German (35) 35
French (21) 21
Russian (17) 17
Spanish (12) 12
Japanese (10) 10
Dutch (5) 5
Polish (4) 4
Portuguese (3) 3
Chinese (2) 2
Hungarian (2) 2
Italian (2) 2
Croatian (1) 1
Danish (1) 1
Indonesian (1) 1
Norwegian (1) 1
Persian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


1. Full Text Blue-Gray Mucocutaneous Discoloration: A New Adverse Effect of Ezogabine
by Garin Shkolnik, Tali and Feuerman, Hana and Didkovsky, Elena and Kaplan, Ilana and Bergman, Reuven and Pavlovsky, Lev and Hodak, Emmilia
JAMA Dermatology, ISSN 2168-6068, 09/2014, Volume 150, Issue 9, pp. 984 - 989
IMPORTANCE: Many drugs have been reported to induce skin and/or mucous membrane discoloration. Ezogabine (retigabine) was recently approved as an add-on drug... 
HYPERPIGMENTATION | DERMATOLOGY | Phenylenediamines - adverse effects | Drug Eruptions - etiology | Anticonvulsants - adverse effects | Humans | Adult | Carbamates - adverse effects | Female | Mucous Membrane | Hypopigmentation - chemically induced | Case studies | Complications and side effects | Care and treatment | Anticonvulsants | Dosage and administration | Pigmentation disorders | Risk factors | Ezogabine
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
2. Full Text Treatment of HCV with ABT-450/r–Ombitasvir and Dasabuvir with Ribavirin
by Feld, Jordan J and Kowdley, Kris V and Coakley, Eoin and Sigal, Samuel and Nelson, David R and Crawford, Darrell and Weiland, Ola and Aguilar, Humberto and Xiong, Junyuan and Pilot-Matias, Tami and DaSilva-Tillmann, Barbara and Larsen, Lois and Podsadecki, Thomas and Bernstein, Barry
The New England Journal of Medicine, ISSN 0028-4793, 04/2014, Volume 370, Issue 17, pp. 1594 - 1603
In this trial in previously untreated patients with HCV genotype 1 infection and no cirrhosis, high rates of sustained response were achieved with three new... 
TRIAL | MEDICINE, GENERAL & INTERNAL | PLUS SOFOSBUVIR | C VIRUS-INFECTION | GENOTYPE 1 INFECTION | DACLATASVIR | SIMEPREVIR TMC435 | HEPATITIS-C | INTERFERON-FREE | TREATMENT-NAIVE PATIENTS | PHASE 2B | Anilides - therapeutic use | Anilides - adverse effects | Humans | Middle Aged | Hepacivirus - genetics | Hepatitis C, Chronic - virology | Male | Viral Load | Young Adult | Ritonavir - adverse effects | Ritonavir - therapeutic use | Adult | Female | Double-Blind Method | Antiviral Agents - therapeutic use | Ribavirin - therapeutic use | Uracil - therapeutic use | Macrocyclic Compounds - adverse effects | Hepatitis C, Chronic - drug therapy | Macrocyclic Compounds - therapeutic use | Uracil - adverse effects | Sulfonamides - therapeutic use | Ribavirin - adverse effects | Antiviral Agents - adverse effects | Adolescent | Sulfonamides - adverse effects | Carbamates - adverse effects | Aged | Carbamates - therapeutic use | Drug Combinations | Uracil - analogs & derivatives | Dosage and administration | Research | Drug therapy, Combination | Hepatitis C | Drug therapy | Ribavirin | Ritonavir | Body weight | Diarrhea | Infections | Nausea | Proteinase inhibitors | Pruritus | Drug resistance | Patients | Genotype & phenotype | Cirrhosis | Sleep disorders | Hepatitis | Asthenia | Hemoglobin | Interferon | Drug dosages | Genotypes
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
3. Full Text Retreatment of HCV with ABT-450/r–Ombitasvir and Dasabuvir with Ribavirin
by Zeuzem, Stefan and Jacobson, Ira M and Baykal, Tolga and Marinho, Rui T and Poordad, Fred and Bourlière, Marc and Sulkowski, Mark S and Wedemeyer, Heiner and Tam, Edward and Desmond, Paul and Jensen, Donald M and Di Bisceglie, Adrian M and Varunok, Peter and Hassanein, Tarek and Xiong, Junyuan and Pilot-Matias, Tami and DaSilva-Tillmann, Barbara and Larsen, Lois and Podsadecki, Thomas and Bernstein, Barry
The New England Journal of Medicine, ISSN 0028-4793, 04/2014, Volume 370, Issue 17, pp. 1604 - 1614
In this trial in patients with HCV genotype 1 infection and no cirrhosis who had previously been treated with peginterferon and ribavirin, retreatment with... 
SUSTAINED VIROLOGICAL RESPONSE | TREATMENT-NAIVE SUBJECTS | TRIAL | PEGINTERFERON/RIBAVIRIN | MEDICINE, GENERAL & INTERNAL | 3-DAY MONOTHERAPY | PLUS RIBAVIRIN | VIRUS-INFECTION | TELAPREVIR | CHRONIC HEPATITIS-C | GENOTYPE 1 INFECTION | Anilides - therapeutic use | Anilides - adverse effects | Humans | Middle Aged | Hepacivirus - genetics | Hepatitis C, Chronic - virology | Male | Viral Load | Young Adult | Ritonavir - adverse effects | Ritonavir - therapeutic use | Adult | Female | RNA, Viral - isolation & purification | Hepacivirus - isolation & purification | Double-Blind Method | Antiviral Agents - therapeutic use | Ribavirin - therapeutic use | Uracil - therapeutic use | Macrocyclic Compounds - adverse effects | Hepatitis C, Chronic - drug therapy | Macrocyclic Compounds - therapeutic use | Retreatment | Uracil - adverse effects | Sulfonamides - therapeutic use | Ribavirin - adverse effects | Antiviral Agents - adverse effects | Adolescent | Sulfonamides - adverse effects | Carbamates - adverse effects | Aged | Carbamates - therapeutic use | Drug Combinations | Uracil - analogs & derivatives | Ritonavir | Infections | RNA polymerase | Pruritus | Patients | Ribavirin | Cirrhosis | Genotype & phenotype | Hepatitis | Hemoglobin | Interferon | Drug therapy | Genotypes
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
4. Full Text The possibility of adverse effect of Kv7-channel opener retigabine on memory processes in rats
by Zwierzyńska, Ewa and Krupa-Burtnik, Agata and Pietrzak, Bogusława
Epilepsy & Behavior, ISSN 1525-5050, 10/2017, Volume 75, pp. 170 - 175
Retigabine is a novel antiepileptic drug with a unique and complex mechanism of action which allows its use in many diseases associated with impaired neuronal... 
MORRIS WATER-MAZE | ACTIVATION | MECHANISM | PSYCHIATRY | HIPPOCAMPAL-LESIONS | ANTICONVULSANT | MODEL | AMNESIA | CLINICAL NEUROLOGY | BEHAVIORAL SCIENCES | SPATIAL MEMORY | CHANNELS | EXPRESSION | Dose-Response Relationship, Drug | Phenylenediamines - adverse effects | Fear | Animals | Anticonvulsants - adverse effects | Spatial Memory - drug effects | Rats, Wistar | Rats | Carbamates - adverse effects | Male | Avoidance Learning - drug effects | Maze Learning - drug effects | Complications and side effects | Anticonvulsants | Memory
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
5. Full Text ABT-450, Ritonavir, Ombitasvir, and Dasabuvir Achieves 97% and 100% Sustained Virologic Response With or Without Ribavirin in Treatment-Experienced Patients With HCV Genotype 1b Infection
by Andreone, Pietro and Colombo, Massimo G and Enejosa, Jeffrey V and Koksal, Iftihar and Ferenci, Peter and Maieron, Andreas and Müllhaupt, Beat and Horsmans, Yves and Weiland, Ola and Reesink, Henk W and Rodrigues, Lino and Hu, Yiran B and Podsadecki, Thomas and Bernstein, Barry
Gastroenterology, ISSN 0016-5085, 2014, Volume 147, Issue 2, pp. 359 - 365.e1
Background & Aims The interferon-free regimen of ABT-450 (a protease inhibitor), ritonavir, ombitasvir (an NS5A inhibitor), dasabuvir (a non-nucleoside... 
Gastroenterology and Hepatology | IFN | PEARL-II | Ribavirin-Free | Interferon-Free Therapy | PLUS RIBAVIRIN | ABT-450/R-OMBITASVIR | VIRUS-INFECTION | TELAPREVIR | SOFOSBUVIR | CHRONIC HEPATITIS-C | COMBINATION | TRIAL | CIRRHOSIS | BOCEPREVIR | GASTROENTEROLOGY & HEPATOLOGY | Anilides - therapeutic use | Puerto Rico | Hepatitis C - drug therapy | United States | Anilides - adverse effects | Humans | Middle Aged | Hepacivirus - genetics | Male | RNA, Viral - blood | Viral Load | Ritonavir - adverse effects | Time Factors | Ritonavir - therapeutic use | Adult | Female | Drug Therapy, Combination | Hepacivirus - drug effects | Antiviral Agents - therapeutic use | Europe | Ribavirin - therapeutic use | Uracil - therapeutic use | Genotype | Treatment Outcome | Macrocyclic Compounds - adverse effects | Biomarkers - blood | Macrocyclic Compounds - therapeutic use | Hepatitis C - diagnosis | Uracil - adverse effects | Sulfonamides - therapeutic use | Ribavirin - adverse effects | Antiviral Agents - adverse effects | Sulfonamides - adverse effects | Carbamates - adverse effects | Hepacivirus - growth & development | Aged | Carbamates - therapeutic use | Uracil - analogs & derivatives | Medical colleges | Care and treatment | Proteases | Ritonavir | Biological products industry | Genetic aspects | Biological response modifiers | Hepatitis C virus | Hepatitis C | Health aspects | Ribavirin
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
6. Full Text Outcome and adverse events in patients with chronic hepatitis C treated with direct-acting antivirals: a clinical randomized study
by Sølund, Christina and Andersen, Ellen S and Mössner, Belinda and Laursen, Alex L and Røge, Birgit T and Kjær, Mette S and Gerstoft, Jan and Christensen, Peer B and Pedersen, Martin S and Schønning, Kristian and Fahnøe, Ulrik and Bukh, Jens and Weis, Nina
European Journal of Gastroenterology & Hepatology, ISSN 0954-691X, 10/2018, Volume 30, Issue 10, pp. 1177 - 1186
OBJECTIVENew potent direct-acting antiviral (DAA) regimens against hepatitis C virus have been approved in recent years. However, information about the rate of... 
ribavirin | ledipasvir and sofosbuvir | hepatitis C virus | ombitasvir and dasabuvir | genotype 1 | adverse events | randomized | direct-acting antivirals | paritaprevir | ACUTE LIVER-FAILURE | VIRUS-INFECTION | SOFOSBUVIR | HCV INFECTION | REAL-WORLD EFFECTIVENESS | SUSTAINED VIROLOGICAL RESPONSE | DASABUVIR | GENOTYPE 1B CIRRHOSIS | RITONAVIR-BOOSTED PARITAPREVIR | GASTROENTEROLOGY & HEPATOLOGY | Anilides - adverse effects | Humans | Middle Aged | Hepacivirus - genetics | Hepatitis C, Chronic - virology | Male | Fatigue - chemically induced | Drug Therapy, Combination - adverse effects | Ritonavir - adverse effects | Adult | Female | Fluorenes - adverse effects | Sofosbuvir - adverse effects | Benzimidazoles - adverse effects | Headache - chemically induced | Antiviral Agents - therapeutic use | Anemia - chemically induced | Genotype | Treatment Outcome | Macrocyclic Compounds - adverse effects | Hepatitis C, Chronic - drug therapy | Uracil - adverse effects | Ribavirin - adverse effects | Antiviral Agents - adverse effects | Sulfonamides - adverse effects | Carbamates - adverse effects | Viral Load - drug effects | Uracil - analogs & derivatives | Drugs | Antiviral agents | Complications and side effects | Treatment outcome | Usage | Analysis | Adverse and side effects | Hepatitis C | Drug therapy | Risk factors
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
7. Full Text Tenofovir alafenamide versus tenofovir disoproxil fumarate, coformulated with elvitegravir, cobicistat, and emtricitabine, for initial treatment of HIV-1 infection: two randomised, double-blind, phase 3, non-inferiority trials
by Sax, Paul E, Dr Prof and Wohl, David, MD and Yin, Michael T, Prof and Post, Frank, MD and DeJesus, Edwin, MD and Saag, Michael, MD and Pozniak, Anton, MD and Thompson, Melanie, MD and Podzamczer, Daniel, MD and Molina, Jean Michel, Prof and Oka, Shinichi, MD and Koenig, Ellen, MD and Trottier, Benoit, MD and Andrade-Villanueva, Jaime, MD and Crofoot, Gordon, MD and Custodio, Joseph M, PharmD and Plummer, Andrew, MS and Zhong, Lijie, PhD and Cao, Huyen, MD and Martin, Hal, MD and Callebaut, Christian, PhD and Cheng, Andrew K, MD and Fordyce, Marshall W, MD and McCallister, Scott, MD and GS-US-292-0104 0111 Study Team and GS-US-292-0104/0111 Study Team
Lancet, The, ISSN 0140-6736, 2015, Volume 385, Issue 9987, pp. 2606 - 2615
Summary Background Tenofovir disoproxil fumarate can cause renal and bone toxic effects related to high plasma tenofovir concentrations. Tenofovir alafenamide... 
Internal Medicine | KIDNEY-DISEASE | RATES | MEDICINE, GENERAL & INTERNAL | ABACAVIR-LAMIVUDINE | BONE-MINERAL DENSITY | SAFETY | ADULTS | ANTIRETROVIRAL THERAPY | LOPINAVIR/RITONAVIR | COUNT | EXPOSURE | Humans | Male | Thiazoles - administration & dosage | Carbamates - administration & dosage | Arthralgia - chemically induced | Thiazoles - adverse effects | Sleep Initiation and Maintenance Disorders - chemically induced | Tenofovir | Adenine - adverse effects | Quinolones - adverse effects | Adult | Anti-HIV Agents - therapeutic use | Deoxycytidine - adverse effects | Female | Headache - chemically induced | Emtricitabine | Adenine - analogs & derivatives | Kidney - drug effects | Respiration Disorders - chemically induced | Double-Blind Method | Anti-HIV Agents - adverse effects | Deoxycytidine - administration & dosage | HIV Infections - virology | Organophosphonates - adverse effects | Treatment Outcome | CD4 Lymphocyte Count | Nausea | Adenine - administration & dosage | Organophosphonates - administration & dosage | Bone Density - drug effects | Quinolones - administration & dosage | Carbamates - adverse effects | HIV Infections - drug therapy | Viral Load - drug effects | Cobicistat | Deoxycytidine - analogs & derivatives | Drug Combinations | Medical colleges | Clinical trials | Cross infection | Nosocomial infections | HIV (Viruses) | Drug therapy | Health aspects | HIV infection | Analysis | Antiretroviral drugs | Infections | Acquired immune deficiency syndrome--AIDS | Human immunodeficiency virus--HIV
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
8. Full Text Simplification to coformulated elvitegravir, cobicistat, emtricitabine, and tenofovir versus continuation of ritonavir-boosted protease inhibitor with emtricitabine and tenofovir in adults with virologically suppressed HIV (STRATEGY-PI): 48 week results of a randomised, open-label, phase 3b, non-inferiority trial
by Arribas, Jose R, Dr and Pialoux, Gilles, Prof and Gathe, Joseph, MD and Di Perri, Giovanni, Prof and Reynes, Jacques, Prof and Tebas, Pablo, MD and Nguyen, Thai, MD and Ebrahimi, Ramin, MS and White, Kirsten, PhD and Piontkowsky, David, MD
Lancet Infectious Diseases, The, ISSN 1473-3099, 2014, Volume 14, Issue 7, pp. 581 - 589
Summary Background Patients with HIV on antiretroviral therapy might benefit from regimen simplification to reduce pill burden and dosing frequency. We aimed... 
Infectious Disease | INFECTIOUS DISEASES | DISOPROXIL FUMARATE | EFAVIRENZ | CO-FORMULATED ELVITEGRAVIR | DOUBLE-BLIND | INITIAL TREATMENT | ANTIRETROVIRAL THERAPY | INFECTED PATIENTS | SINGLE-TABLET REGIMEN | ADHERENCE | HAART | Humans | Middle Aged | Male | Thiazoles - therapeutic use | Thiazoles - adverse effects | Tenofovir | Deoxycytidine - therapeutic use | Drug Therapy, Combination - adverse effects | Adenine - adverse effects | Quinolones - adverse effects | Ritonavir - adverse effects | Adenine - therapeutic use | Quinolones - therapeutic use | Protease Inhibitors - adverse effects | Ritonavir - therapeutic use | Adult | Anti-HIV Agents - therapeutic use | Deoxycytidine - adverse effects | Female | Protease Inhibitors - therapeutic use | Emtricitabine | Adenine - analogs & derivatives | Organophosphonates - therapeutic use | Anti-HIV Agents - adverse effects | Organophosphonates - adverse effects | Drug Therapy, Combination - methods | HIV | Carbamates - adverse effects | HIV Infections - drug therapy | Carbamates - therapeutic use | Viral Load - drug effects | Cobicistat | Deoxycytidine - analogs & derivatives | Adults | Protease inhibitors | Proteases | Antiretroviral drugs | Patient satisfaction | Drug therapy | Laboratories | Human immunodeficiency virus--HIV
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
9. Full Text Ombitasvir, Paritaprevir Co-dosed With Ritonavir, Dasabuvir, and Ribavirin for Hepatitis C in Patients Co-infected With HIV-1: A Randomized Trial
by Sulkowski, Mark S and Eron, Joseph J and Wyles, David and Trinh, Roger and Lalezari, Jay and Wang, Chia and Slim, Jihad and Bhatti, Laveeza and Gathe, Joseph and Ruane, Peter J and Elion, Richard and Bredeek, Fritz and Brennan, Robert and Blick, Gary and Khatri, Amit and Gibbons, Krystal and Hu, Yiran B and Fredrick, Linda and Schnell, Gretja and Pilot-Matias, Tami and Tripathi, Rakesh and Da Silva-Tillmann, Barbara and McGovern, Barbara and Campbell, Andrew L and Podsadecki, Thomas
JAMA, ISSN 0098-7484, 03/2015, Volume 313, Issue 12, pp. 1223 - 1231
IMPORTANCE: Patients co-infected with human immunodeficiency virus (HIV) and hepatitis C virus (HCV) are at high risk for liver disease progression. However,... 
MEDICINE, GENERAL & INTERNAL | ABT-450/R-OMBITASVIR | VIREMIA | THERAPY | IMMUNODEFICIENCY-VIRUS INFECTION | PEGYLATED INTERFERON | ALPHA-2A PLUS RIBAVIRIN | GENOTYPE 1 INFECTION | COINFECTION | HCV | PREVALENCE | HIV-1 | Coinfection | Hepatitis C - drug therapy | Anilides - adverse effects | Humans | Middle Aged | Hepacivirus - genetics | Male | Carbamates - administration & dosage | Ritonavir - adverse effects | Uracil - administration & dosage | Ribavirin - administration & dosage | Adult | Female | Hepatitis C - complications | Drug Therapy, Combination | Ritonavir - administration & dosage | Treatment Outcome | Macrocyclic Compounds - adverse effects | Antiviral Agents - administration & dosage | Pilot Projects | Uracil - adverse effects | Anilides - administration & dosage | Ribavirin - adverse effects | HIV Infections - complications | Sulfonamides - adverse effects | Carbamates - adverse effects | HIV Infections - drug therapy | Macrocyclic Compounds - administration & dosage | Sulfonamides - administration & dosage | Uracil - analogs & derivatives | Drugs | Clinical trials | Hepatitis | Human immunodeficiency virus--HIV | Medical treatment | Index Medicus | Abridged Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
10. Full Text Sofosbuvir, Velpatasvir, and Voxilaprevir for Previously Treated HCV Infection
by Bourlière, Marc and Gordon, Stuart C and Flamm, Steven L and Cooper, Curtis L and Ramji, Alnoor and Tong, Myron and Ravendhran, Natarajan and Vierling, John M and Tran, Tram T and Pianko, Stephen and Bansal, Meena B and de Lédinghen, Victor and Hyland, Robert H and Stamm, Luisa M and Dvory-Sobol, Hadas and Svarovskaia, Evguenia and Zhang, Jie and Huang, K.C and Subramanian, G. Mani and Brainard, Diana M and McHutchison, John G and Verna, Elizabeth C and Buggisch, Peter and Landis, Charles S and Younes, Ziad H and Curry, Michael P and Strasser, Simone I and Schiff, Eugene R and Reddy, K. Rajender and Manns, Michael P and Kowdley, Kris V and Zeuzem, Stefan and POLARIS-1 and POLARIS-4 Investigators and POLARIS-1 and POLARIS-4 Investigators
The New England Journal of Medicine, ISSN 0028-4793, 06/2017, Volume 376, Issue 22, pp. 2134 - 2146
In two trials involving patients with hepatitis C in whom previous treatment with direct-acting antiviral agents failed, treatment for 12 weeks with... 
GENOTYPE 1 | MEDICINE, GENERAL & INTERNAL | THERAPY | HEPATITIS-C VIRUS | EFFICACY | PROTEASE INHIBITOR GS-9857 | RESISTANCE | DIRECT-ACTING ANTIVIRALS | OPEN-LABEL | COMBINATION | PHASE-2 TRIAL | Hepatitis C - drug therapy | Humans | Middle Aged | Drug Resistance, Viral | Hepacivirus - genetics | Male | Heterocyclic Compounds, 4 or More Rings - therapeutic use | Aged, 80 and over | Adult | Female | Hepatitis C - complications | Sofosbuvir - adverse effects | Protease Inhibitors - therapeutic use | Hepacivirus - drug effects | Sofosbuvir - therapeutic use | Liver Cirrhosis - etiology | Antiviral Agents - therapeutic use | Genotype | Heterocyclic Compounds, 4 or More Rings - adverse effects | Macrocyclic Compounds - adverse effects | Macrocyclic Compounds - therapeutic use | Sulfonamides - therapeutic use | Antiviral Agents - adverse effects | Hepatitis C - virology | Sulfonamides - adverse effects | Carbamates - adverse effects | Aged | Carbamates - therapeutic use | Viral Nonstructural Proteins - antagonists & inhibitors | Drug Combinations | Care and treatment | Hepatitis C virus | Drug therapy | Patients | Health aspects | Headache | Antiretroviral drugs | Antiviral agents | Proteinase | Clinical trials | Diarrhea | Fatigue | Nausea | Cirrhosis | Hepatitis | Genotypes | Pharmaceuticals
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
11. Full Text Management of Treatment‐Related Adverse Events with Agents Targeting the MAPK Pathway in Patients with Metastatic Melanoma
by Daud, Adil and Tsai, Katy
The Oncologist, ISSN 1083-7159, 07/2017, Volume 22, Issue 7, pp. 823 - 833
Tremendous progress has been made in the clinical landscape of advanced‐stage BRAF V600–mutant melanoma treatment over the past 5 years. Targeted therapies... 
BRAF | Mitogen‐activated protein kinase signaling system | Drug‐related side effects and adverse reactions | Protein kinase inhibitors | Melanoma | Mitogen-activated protein kinase signaling system | Drug-related side effects and adverse reactions | IMPROVED SURVIVAL | PHASE-3 | COMBINATION | COMBINED DABRAFENIB | THERAPY | MEK INHIBITION | ONCOLOGY | DOUBLE-BLIND | COBIMETINIB | BRAF-MUTANT MELANOMA | VEMURAFENIB | Oximes - adverse effects | Humans | Fever - therapy | Oximes - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Imidazoles - administration & dosage | Carbamates - administration & dosage | Protein Kinase Inhibitors - adverse effects | Fever - chemically induced | Pyridones - administration & dosage | Benzimidazoles - administration & dosage | Antineoplastic Agents - adverse effects | Benzimidazoles - adverse effects | Skin Diseases - chemically induced | Piperidines - administration & dosage | Imidazoles - adverse effects | Pyrimidinones - adverse effects | Azetidines - adverse effects | Mitogen-Activated Protein Kinase Kinases - antagonists & inhibitors | Melanoma - pathology | Proto-Oncogene Proteins B-raf - antagonists & inhibitors | Vemurafenib | Azetidines - administration & dosage | Indoles - adverse effects | Proto-Oncogene Proteins B-raf - genetics | Melanoma - drug therapy | Piperidines - adverse effects | Sulfonamides - adverse effects | Carbamates - adverse effects | Pyrimidinones - administration & dosage | Pyridones - adverse effects | Sulfonamides - administration & dosage | Melanoma and Cutaneous Malignancies
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights